Pharmacogenetics
PharmacoGenetics (PGx) – a Companion Diagnostic
A Pharmacogenetic test helps you choose the right medication and dose for your patient to deliver the best possible outcome and avoid adverse drug reactions. Without a PGx test, you do not know if your patient has a DNA variant which can result in them getting too much or too little of a drug, despite the dose being a standard dose. Many drugs, that your patients may need one day, have been studied for known DNA sequence variants (statins, anaesthetics, anti-blood clotting meds, anti-hypertensives, opioids, antibiotics, anti-diabetics) and guidelines exist to protect your patient. PGx is highly useful as a companion or pre-emptive test in cardiology and can be used post treatment, to explain why inefficacy or adverse drug reaction were observed.
The vast majority of individuals have one or more pharmacogenetic variants. In a study involving
over 1,000 patients1, 99% of them carried at least one genetic variation impacting medication.
Pharmacogenetics (PGx) test:
This test is designed to reduce adverse drug side effects and improve drug efficacy.
Test request form:https://www.eurofins-biomnis.com/referentiel/liendoc/renseignements/INTGB/B110-INTGB-Profil_pharmacogenetique.pdf
